TY - JOUR
T1 - Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
AU - Magbanua, Mark Jesus M.
AU - Hendrix, Laura H.
AU - Hyslop, Terry
AU - Barry, William T.
AU - Winer, Eric P.
AU - Hudis, Clifford
AU - Toppmeyer, Deborah
AU - Carey, Lisa Anne
AU - Partridge, Ann H.
AU - Pierga, Jean Yves
AU - Fehm, Tanja
AU - Vidal-Martínez, José
AU - Mavroudis, Dimitrios
AU - Garcia-Saenz, Jose A.
AU - Stebbing, Justin
AU - Gazzaniga, Paola
AU - Manso, Luis
AU - Zamarchi, Rita
AU - Antelo, María Luisa
AU - Mattos-Arruda, Leticia De
AU - Generali, Daniele
AU - Caldas, Carlos
AU - Munzone, Elisabetta
AU - Dirix, Luc
AU - Delson, Amy L.
AU - Burstein, Harold J.
AU - Qadir, Misbah
AU - Ma, Cynthia
AU - Scott, Janet H.
AU - Bidard, François Clément
AU - Park, John W.
AU - Rugo, Hope S.
N1 - Publisher Copyright:
© 2020 The Author(s). Published by Oxford University Press. All rights reserved.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Background: We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods: Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS. Results: Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9%), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P <. 001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model. Conclusions: We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.
AB - Background: We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods: Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS. Results: Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9%), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P <. 001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model. Conclusions: We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.
UR - http://www.scopus.com/inward/record.url?scp=85098011041&partnerID=8YFLogxK
U2 - 10.1093/jnci/djaa113
DO - 10.1093/jnci/djaa113
M3 - Article
C2 - 32770247
AN - SCOPUS:85098011041
SN - 0027-8874
VL - 113
SP - 443
EP - 452
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 4
ER -